SS Innovations International Reports Record Q2 Revenue as Surgical Robot Demand Surges

SS Innovations International (NASDAQ: SSII) has reported record second-quarter 2026 revenue of $13.9 million, a 39.4% increase from $10 million in the same period last year, driven by a 30.4% rise in installations of its SSi Mantra surgical robotic system to 30 units. The company's gross profit climbed 20% to $7.1 million, yielding a gross margin of 50.9%, while its net loss widened to $2.7 million, or $0.01 per diluted share, compared with a net loss of $0.3 million a year earlier. For the first half of the year, revenue surged 65.6% to $25 million, with installations up 47.4% to 56 systems. As of June 30, SS Innovations held $13.6 million in cash and cash equivalents, had no long-term debt, and boasted a cumulative installed base of 224 SSi Mantra systems across 12 countries.

The financial results reflect the company's strategic focus on making robotic surgery affordable and accessible globally, particularly in emerging markets. The SSi Mantra's cost-effectiveness and user-friendly design have driven its adoption, with cumulative procedures reaching 12,272 as of June 30, including 175 telesurgeries. Notably, the company recently completed a robotic telesurgery spanning more than 13,600 miles between Colombia and India, demonstrating the system's capability to facilitate remote surgical expertise across vast distances. This achievement underscores the potential for telesurgery to bridge healthcare gaps in underserved regions.

Regulatory progress is a key catalyst for future growth. SS Innovations expects the U.S. Food and Drug Administration to complete its review of the company's 510(k) premarket notification for the SSi Mantra by the end of the first quarter of 2027, which would open the lucrative U.S. market. Additionally, the company believes it can obtain European Union CE marking certification by the end of 2026, paving the way for entry into European markets. These milestones are critical as the company seeks to expand its global presence beyond its current 12-country footprint.

The strong first-half performance and regulatory momentum position SS Innovations to capitalize on the growing demand for minimally invasive surgical options. The company's focus on affordability and accessibility resonates with healthcare providers in cost-sensitive environments, where traditional robotic systems like Intuitive Surgical's da Vinci are often prohibitively expensive. As SS Innovations continues to scale its operations and achieve regulatory clearances, it is poised to disrupt the surgical robotics market, potentially democratizing access to advanced surgical care worldwide.

Investors and industry observers are watching closely as SS Innovations navigates the path to broader commercialization. The company's financial discipline, with no long-term debt and a healthy cash position, provides a solid foundation for its expansion plans. With the anticipated regulatory approvals and a growing installed base, SS Innovations is well-positioned to deliver on its mission of making robotic surgery a standard of care across the globe. For more details, visit the full press release at https://ibn.fm/nTMso.